Photo: Female researcher using a machine in the lab


Ocrelizumab was licensed by the European Medicines Agency in January 2018.

Read more about this licence

In March 2017 it was approved by the US Food and Drug Administration (FDA) as a treatment for both relapsing and primary progressive MS.

Earlier this year in June 2018  NICE approved it for treating relapsing MS. In September 2018, NICE rejected the use of ocrelizumab for primary progressive MS. We're campaigning to change that.

Add your voice to call for ocrelizumab for primary progressive MS

Ocrelizumab is an intravenous infusion treatment that has been developed by Roche.

Current phase of trial: Licensed

Type of MS: primary progressive and relapsing MS

Find out more about ocrelizumab